KRAS and non-small cell lung carcinoma: Diverse point mutations exist within KRAS, the majority of which affect codon 12 of the protein in NSCLC (Figure 1), leading to amino acid substitutions that impair the intrinsic hydrolytic activity and render the KRAS oncoprotein constitutively active.